NCT02659085View on ClinicalTrials.gov

Ketamine as an Alternative Treatment to ECT in Major Depressive Disorder

PHASE2/PHASE3CompletedINTERVENTIONAL

Enrollment

198

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

August 31, 2019

Study Completion Date

August 31, 2019

Conditions

Depressive Disorder, Major

Interventions

DRUG

Ketamine IV Infusion

Patients randomized to the experimental treatment receive intravenous infusions of racemic ketamine (0.5 mg/kg), delivered over a period of forty minutes thrice weekly (Monday, Wednesday, Friday) under supervision.

PROCEDURE

ECT

ECT given in line with standard procedures (including anesthesia, muscle relaxation and oxygenation) thrice weekly.

Trial Locations (1)

221 85

Department of Psychiatry, Lund

All Listed Sponsors

lead

Pouya Movahed Rad

OTHER

NCT02659085 - Ketamine as an Alternative Treatment to ECT in Major Depressive Disorder | Biotech Hunter | Biotech Hunter